Price
CHART BY
Frequently asked questions
What is Incyte's market capitalization?
The market capitalization of Incyte is $24.92B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is Incyte's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for Incyte is 15.67. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for Incyte?
Incyte's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $7.846. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Incyte's stock?
Currently, 31 analysts cover Incyte's stock, with a consensus target price of $128.91. Analyst ratings provide insights into the stock's expected performance.
What is Incyte's revenue over the trailing twelve months?
Over the trailing twelve months, Incyte reported a revenue of $5.82B.
What is the EBITDA for Incyte?
Incyte's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $1.94B. EBITDA measures the company's overall financial performance.
What is the free cash flow of Incyte?
Incyte has a free cash flow of $1.92B. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Incyte have, and what sector and industry does it belong to?
Incyte employs approximately 2,844 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Incyte's shares?
The free float of Incyte is 200.85M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $24.92B
- EPS (TTM)
- $7.846
- Free Float
- 200.85M
- P/E ratio (TTM)
- 15.67
- Revenue (TTM)
- $5.82B
- EBITDA (TTM)
- $1.94B
- Free Cashflow (TTM)
- $1.92B
Pricing
- 1D span
- $121.42$124.61
- 52W span
- $81.09$132.58
Analyst Ratings
The price target is $128.91 and the stock is covered by 31 analysts.
Buy
13
Hold
16
Sell
2
Information
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded on April 8, 1991 and is headquartered in Wilmington, DE.
- Employees
- 2,844
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- INCY
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet